The PrenaTest from LifeCodexx, Germany, is Europe’s first noninvasive molecular diagnostic test to determine fetal chromosomal aneuploidies from maternal blood. It may be used without restriction following all methods of fertility treatment, including IVF and egg donation, after the 9th week of gestation. The test has been validated in several studies totaling 870 samples from singleton and multiple pregnancies, and provided a clear result in 99.8% of all performed analyses. With a false positive rate of 0.1%, the test further clarifies early diagnosis of fetal malformation, reducing the number of unnecessary and invasive examinations of non-affected pregnancies. For more information, visit LifeCodexx.